[Derivatives of androstenediol & their therapeutic application]. 1957

L ISRAEL

UI MeSH Term Description Entries
D000728 Androgens Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. Androgen,Androgen Receptor Agonist,Androgen Effect,Androgen Effects,Androgen Receptor Agonists,Androgenic Agents,Androgenic Compounds,Agents, Androgenic,Agonist, Androgen Receptor,Agonists, Androgen Receptor,Compounds, Androgenic,Effect, Androgen,Effects, Androgen,Receptor Agonist, Androgen,Receptor Agonists, Androgen
D015114 Androstenediol An intermediate in TESTOSTERONE biosynthesis, found in the TESTIS or the ADRENAL GLANDS. Androstenediol, derived from DEHYDROEPIANDROSTERONE by the reduction of the 17-keto group (17-HYDROXYSTEROID DEHYDROGENASES), is converted to TESTOSTERONE by the oxidation of the 3-beta hydroxyl group to a 3-keto group (3-HYDROXYSTEROID DEHYDROGENASES). 5-Androstene-3,17-diol,5-Androstene-3beta-17beta-Diol,Androst-5-ene-3 beta,17 beta-Diol,Androst-5-ene-3,17-diol,Bisexovister,Delta 5-Androstenediol,Hermaphrodiol,delta 5-Androstene-3 beta,17 beta-Diol,5 Androstene 3,17 diol,5 Androstene 3beta 17beta Diol,Androst 5 ene 3 beta,17 beta Diol,Androst 5 ene 3,17 diol,Delta 5 Androstenediol,delta 5 Androstene 3 beta,17 beta Diol

Related Publications

L ISRAEL
June 1954, Gazzetta medica italiana,
L ISRAEL
December 1952, American journal of obstetrics and gynecology,
L ISRAEL
January 1946, Revue canadienne de biologie,
L ISRAEL
April 1966, Meditsinskaia sestra,
L ISRAEL
April 1958, Progresos de terapeutica clinica,
Copied contents to your clipboard!